Camile de Moraes1,2,+, José Cássio de Moraes3, Gabriela Drummond Marques da Silva4, Elisabeth Carmen Duarte1
1Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical, Brasília, DF, Brasil
2Ministério da Saúde, Secretaria de Vigilância em Saúde, Brasília, DF, Brasil
3Faculdade de Ciências Médicas da Santa Casa, São Paulo, SP, Brasil
4Universidade de Brasília, Faculdade de Ciências da Saúde, Programa de Pós-Graduação em Saúde Coletiva, Brasília, DF, Brasil
BACKGROUND Meningococcal C conjugate (MenC) vaccine was introduced as part of the Brazilian National Immunisation Program in 2010 for children < 1 year of age.
OBJECTIVES The study objective was to evaluate the impact of this vaccination strategy.
METHODS An observational, mixed ecological and analytical study was conducted, based on time series panel data from surveillance records (2001-2013).
FINDINGS A total of 37,538 of meningococcal disease cases were recorded during the study period. Of these, 19,997 were attributed to serogroup C. A decrease in meningococcal disease serogroup C (MDC) incidence among children aged 1 year [65.2%; 95% confidence interval (CI): 20.5-84.7%] and 1-4 years (46.9%; 95%CI: 14.6-79.1%) were found in the three years following vaccination introduction. Vaccination impact on the reduction of MDC incidence varied from83.7% (95%CI: 51.1-100.0%) in the Midwest region to 56.7% (95%CI: 37.4-76.0%) in the Northeast region.
MAIN CONCLUSIONS Vaccination against MDC in Brazil had a positive impact on the population of children aged 1 year, across all regions, and on the 1-4 year-old cohort. Nevertheless, in our view there is scope for iproving the vaccination strategy adopted in Brazil.
+ Corresponding author:
Received 26 April 2016
Accepted 15 December 2016